SAN DIEGO – January , 2023 – Vividion Therapeutics, Inc., (Vividion) a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced that current President and Head of Research and Development Aleksandra Rizo, M.D., Ph.D., will assume the role of President and Chief Executive Officer of Vividion and will join the Board of Directors. Jeffrey Hatfield, current Chief Executive Officer, will transition to the position of Chairman of the Board of Directors at Vividion. Vividion will continue its mission to unlock high value, traditionally undruggable target biology with precision therapeutics for cancers and immune disorders.
Under Jeffrey Hatfield’s leadership since 2020, Vividion has grown from a small, research startup to a mid-sized successful biotech company with nearly 200 employees. The company is already advancing multiple novel biology, first-in-class programs towards the clinic and has more than a dozen similar pipeline opportunities emerging in early discovery. In his new role, Jeffrey Hatfield will continue to take an active role in the growth and maturation of Vividion towards a clinical-stage company, providing guidance and support on both corporate and R&D strategy.
“It is an incredibly exciting time at Vividion, as we are starting to advance multiple programs from our chemoproteomics platform in the clinic and our research pipeline and strategic partnerships continue to accelerate, said Jeffrey Hatfield. “I’m deeply grateful for the opportunity over the past two years to lead this world-class team at Vividion, and to partner with Bayer to realize our full potential. In my new role as Board Chair, I look forward to continuing to work with the Board and Aleksandra to bring our precision therapeutics to the patients who desperately need them.”
“Jeff has been a key driving force behind Vividion’s growth. We are very grateful for his visionary leadership and pleased that he will continue to work closely with us in his new role as Chairman of the Board,” said Stefan Oelrich, Member of the Board of Management of Bayer AG and President of Bayer’s Pharmaceuticals Division. “With Aleksandra as the new CEO, I am certain Vividion will continue to thrive and advance in its mission to bring transformative treatments to patients. We are excited about the future ahead and look forward to working with this highly-respected leader.”
Since joining Vividion in 2022, Aleksandra Rizo has been the leader of the company’s Research and Development organization, helping to shape the portfolio and advance the chemoproteomics platform. To aid in the transition to Vividion’s next phase of growth, Aleksandra Rizo has extensive industry leadership experience building a small biotech as well as a deep understanding of how to work and thrive within a large pharmaceutical ecosystem. An accomplished clinician and oncology expert with a true entrepreneurial spirit, Aleksandra Rizo has brought various programs from discovery, through clinical development to submission, a critical skill as the Vividion pipeline matures.
“We have begun our journey to change medicine and remove the boundaries of druggability for a variety of diseases including cancer and immune disorders,” states Aleksandra Rizo. “Our programs are nearly all targeting proteins the industry has previously viewed as undruggable and indicate the potential to deliver enormous value to patients, if successful. I look forward to working with Jeff and the Board as we continue to excel in our discovery efforts and transition into a clinical-stage company. I cannot imagine a more exciting time to lead Vividion.”
Vividion Therapeutics, Inc. a wholly owned and independently operated subsidiary of Bayer AG acquired in August 2021, is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. The company’s platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets. The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. For more information, please visit www.vividion.com.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses, before special items, amounted to 5.3 billion euros. For more information, go to www.bayer.com.